Press releases

Company no longer markets or sells the NIR stent; findings will not affect Boston Scientific's ability to sell its market-leading TAXUS stent systems.

Company's Quincy Distribution Center approved as a sterilization site for its Cutting Balloon™ microsurgical dilatation device product line.

Company recognized for its achievements in lean manufacturing at its Minnesota facility

A live webcast and replay of the March 15th session will be available. Learn how to tune in.

Trial is designed to analyze "real-world" outcomes for patients with gastroesophageal reflux disease (GERD).

Johnson & Johnson trial results add to the extensive body of clinical evidence reinforcing the safety profile of Company’s TAXUS system.

Nine-month study data presented at the annual American College of Cardiology scientific session in Orlando.

(March 4, 2005) -- Boston Scientific Corporation (NYSE:BSX) today announced that it has completed its acquisition of Advanced Stent Technologies, Inc. (AST) of Pleasanton, California, for an...

(March 3, 2005) -- Boston Scientific Corporation (NYSE: BSX) today announced the schedule of the Company's major events at the American College of Cardiology annual scientific session, which runs...

TAXUS OLYMPIC registry plans to enroll more than 30,000 patients at more than 600 centers in the United States, Europe and other international locations.

ATLAS clinical trial is the first trial using Boston Scientific's new Liberté™ coronary stent as a platform for its paclitaxel-eluting coronary stent system.

Announcement confirms the safety and efficacy of coil embolization for the treatment of ruptured and unruptured brain aneurysms.

A live webcast and replay of the Feb. 8th session will be available. Learn how to tune in for the presentation.

At a meeting with analysts and investors, Company provided ranges for both sales and earnings goals for the three-year period.

Next-generation stent system has been launched in 18 countries.

On February 1, Company will provide financial guidance for 2005, and financial goals for 2006 and 2007. Learn how to tune in.

A live webcast and replay of the January 25th session will be available. Learn how to tune in for the presentation.

Marks a major milestone for the Company and for the treatment of coronary artery disease.

Launch of TAXUS™ Liberté™ paclitaxel-eluting coronary stent system in 18 countries provides physicians state-of-the-art drug-eluting stent technology for the treatment of coronary artery disease.

The announcement was made by Jim Tobin, President and Chief Executive Officer, at the JPMorgan Healthcare Conference in San Francisco.

U.S. District Court in Delaware granted summary judgment of non-infringement in favor of Boston Scientific.

A live webcast and replay of the January 10th session will be available. Learn how to tune in for the presentation.

Jim Tobin, President and CEO, calls Company’s 2004 performance “nothing short of remarkable and speaks to a truly global effort."

Money is being directed to the Red Cross' International Response Fund.

Expansion of management structure is designed to position the Company for continued growth and success.

The transaction is expected to close early next year.

Motions for summary judgment were granted in part and denied in part.

A live webcast and replay of the December 1 conference session will be available.

An existing licensing agreement with Angiotech Pharmaceuticals, Inc. allows Company to obtain an exclusive license for the use of paclitaxel and other agents in the coronary vascular field.

French government adds new patient categories to reimbursement approval criteria.

Company plans to use the proceeds to repay commercial paper borrowings and for other general corporate purposes.

Equity investment in a privately held company developing a balloon-expandable, bioresorbable drug-eluting stent.

The two series of senior notes will have varied maturities and a combined aggregate principal amount of $500 million.

A live webcast and replay of the November 18 conference session will be available.

Company subsidiary will resume worldwide distribution after a voluntary recall of all unimplanted cochlear implant systems.

TAXUS™ Express2™ paclitaxel-eluting coronary stent system will be the subject of 15 presentations.

A live webcast and replay of the November 10 conference session will be available.

Patients with Gastroesophageal Reflux Disease (GERD) reported substantial improvements after the Enteryx® Procedure.

and Orlando, FL (November 2, 2004)-- Boston Scientific Corporation (NYSE: BSX) today announced results supporting the efficacy of the Enteryx Procedure in relieving the symptoms of...

and Orlando, FL (November 2, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced two-year follow-up data from its ongoing Enteryx Procedure clinical trial for the treatment of...

Innovative uterine fibroid embolization (UFE) procedure is a less-invasive treatment option for fibroids.

Full line of mid-urethral sling products for the treatment of female stress urinary incontinence.

ARRIVE 2 registry program plans to enroll 5,000 patients at approximately 60 centers in the United States.

Repurchased shares will be made available for issuance under the Company's equity incentive plans and for general corporate purposes.

“This quarter was one of the best performances in our history," said Jim Tobin, President and CEO.

Company will launch the product immediately.

A live webcast and replay of the Tuesday, October 19 conference call will be available.

Registries studied more than 7,000 patients at 236 sites around the globe; results consistent with controlled TAXUS studies.

The results support early safety, which is consistent with results from previous TAXUS clinical trials.

Benefits reported at 12 months were maintained at two years.

The data demonstrated that the safety and efficacy benefits associated with the TAXUS stent system were maintained at two years.

Company will make a special one-time contribution to its U.S. 401(k) Retirement Savings Plan and increase match amounts to six percent of pay.

Subsidiary Advanced Bionics Corporation is voluntarily recalling worldwide all unimplanted CLARION® and HiResolution® cochlear implants.

Together, studies presented will represent more than 10,000 patients.

Galway facility is one of two Company facilities that manufacture the TAXUS™ Express2™ paclitaxel-eluting coronary stent system.

Preliminary worldwide sales of TAXUS systems for the month of August were approximately $200 million.

Registry designed to assess physician usage patterns and evaluate outcome data in "real world" patients.

ATLAS clinical trial is the first trial using Boston Scientific's new Liberté™ coronary stent as a platform for its paclitaxel-eluting coronary stent system.

A live webcast and replay of the September 1 conference call will be available.

Company will launch the device immediately

Company plans to launch the product in the United States immediately.

Extended expiration date applies to all sizes of the TAXUS system for sale in the United States.

Seattle device company is developing a neurostimulation system whose initial application focused on treating stroke patients.

"We experienced impressive growth across all our businesses and regions," said Jim Tobin, President and Chief Executive Officer.

ATLAS is the first clinical trial using Boston Scientific's new Liberté coronary stent as a platform for its paclitaxel-eluting coronary stent system.

A live webcast and replay of the July 26 conference call will be available.

"Patient safety continues to be our highest priority," said Jim Tobin, President and Chief Executive Officer.

Prospective, multi-center, randomized study designed to evaluate the benefits of filter-based embolic protection during primary percutaneous coronary intervention (PCI) in acute myocardial infarction (AMI).

The voluntary recall does not affect patients who have already received a TAXUS stent.

Company plans to use the proceeds to repay commercial paper borrowings and for other general corporate purposes.

Company announces launch of a public offering of $500 million aggregate principal amount of senior notes.

A live webcast and replay of the June 9th conference session will be available.

Company estimates that its share of the U.S. drug-eluting stent market - as of May 31st - continues to be in excess of 70 percent, on a reorder basis.

Acquisition will bring neuromodulation technology, including a range of neurostimulators, programmable drug pumps and cochlear implants.

(May 28, 2004) -- Boston Scientific Corporation (NYSE: BSX) announced today that the U.S. Court of Appeals for the Federal Circuit has affirmed a decision by the U.S. District Court in Wilmington,...

Trial assessed the safety and efficacy of a moderate-release formulation paclitaxel-eluting stent in high-risk patients, including long lesions with overlapping stents, small vessels and diabetics.

Company made the announcement at the annual Paris Course on Revascularization, the largest interventional cardiology conference in Europe.

Company expects to announce 30-day results at the 2004 Transcatheter Cardiovascular Therapeutics conference in September.

A replay of the May 26 analyst meeting will also be available. Learn how to tune into the webcast.

Enteryx found equally effective in controlling GERD symptoms in patients previously treated with proton pump inhibitor (PPI) medications at both standard and high dosing.

Company made the announcement at the annual Digestive Disease Week (DDW) conference.

A live webcast and replay of the May 19 conference session will be available.

"The TAXUS launch continues to go extremely well, with sales growing and execution remaining strong," said Jim Tobin, President and Chief Executive Officer.

Company estimates that its share of the U.S. drug-eluting stent market - as of May 14 - continues to be in excess of 70 percent, on a reorder basis.

A live webcast and replay of the May 6 conference session will be available. Read more.

"This quarter saw the achievement of a major milestone for Boston Scientific with the successful launch of TAXUS in the U.S.," said Jim Tobin, President and CEO.

Combines features from two of Boston Scientific's breakthrough technologies.

(April 14, 2004) -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the first quarter ended March 31, 2004 on Tuesday, April 20, at 9:00...

(April 8, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced the U.S. launch of its Sentinol™ Self-Expanding Nitinol Biliary Stent System (Sentinol), which has been cleared by...

(April 7, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced that it has acquired Precision Vascular Systems, Inc. (Precision Vascular), a privately held company located in West...

(April 5, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced preliminary results related to U.S. sales of its TAXUS™ Express2™ paclitaxel-eluting coronary stent system and...

(April 1, 2004) -- Boston Scientific Corporation (NYSE: BSX) announced today that the European Patent Office has declared invalid a patent held by Medinol Ltd. This is the patent that Boston...

(March 31, 2004) -- Boston Scientific Corporation (NYSE: BSX) announced today that it has concluded enrollment in its TAXUS V de novo lesion clinical trial. The Company has enrolled 1,172...

(March 29, 2004) -- Boston Scientific Corporation (NYSE: BSX) announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its Contour SE™...

(March 25, 2004) -- Boston Scientific Corporation (NYSE: BSX) and EndoTex Interventional Systems, Inc. announced today the completion of enrollment in a carotid artery stenting clinical trial to...

(March 22, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced preliminary information related to U.S. sales of its TAXUS™ Express2™ paclitaxel-eluting coronary stent system....

(December 2, 2005) -- Boston Scientific Corporation (NYSE: BSX) today announced that it is voluntarily recalling all Stainless Steel Greenfield® Vena Cava Filters with 12Fr Femoral Introducer...

(March 4, 2004) - Boston Scientific Corporation (NYSE: BSX) announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market its TAXUS™ Express2™...

(March 4, 2004) - Boston Scientific Corporation (NYSE: BSX) today announced that it has completed a land purchase in Kerkrade, the Netherlands. The site will house the Company's new distribution...

(February 26, 2004) -- Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 7th Annual Lehman Brothers' 2004 Global Healthcare Conference, which is being held March 3-5 in...